190 related articles for article (PubMed ID: 21351502)
1. [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
Cai YC; Zou Y; Xian LJ
Yao Xue Xue Bao; 2010 Mar; 45(3):283-8. PubMed ID: 21351502
[TBL] [Abstract][Full Text] [Related]
2. Disrupting tumour blood vessels.
Tozer GM; Kanthou C; Baguley BC
Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
[TBL] [Abstract][Full Text] [Related]
3. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
4. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth.
Pérez-Pérez MJ; Priego EM; Bueno O; Martins MS; Canela MD; Liekens S
J Med Chem; 2016 Oct; 59(19):8685-8711. PubMed ID: 27348355
[TBL] [Abstract][Full Text] [Related]
5. New vascular disrupting agents in upper gastrointestinal malignancies.
Quatrale AE; Porcelli L; Gnoni A; Numico G; Paradiso A; Azzariti A
Curr Med Chem; 2014; 21(8):1039-49. PubMed ID: 23992324
[TBL] [Abstract][Full Text] [Related]
6. Vascular disrupting agents in clinical development.
Hinnen P; Eskens FA
Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
[TBL] [Abstract][Full Text] [Related]
7. AVE8062: a new combretastatin derivative vascular disrupting agent.
Delmonte A; Sessa C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in vascular disrupting agents in cancer therapy.
Porcù E; Bortolozzi R; Basso G; Viola G
Future Med Chem; 2014 Sep; 6(13):1485-98. PubMed ID: 25365233
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular toxicity profiles of vascular-disrupting agents.
Subbiah IM; Lenihan DJ; Tsimberidou AM
Oncologist; 2011; 16(8):1120-30. PubMed ID: 21742963
[TBL] [Abstract][Full Text] [Related]
10. Vascular disrupting agents in cancer therapy.
Smolarczyk R; Czapla J; Jarosz-Biej M; Czerwinski K; Cichoń T
Eur J Pharmacol; 2021 Jan; 891():173692. PubMed ID: 33130277
[TBL] [Abstract][Full Text] [Related]
11. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Ji YT; Liu YN; Liu ZP
Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
[TBL] [Abstract][Full Text] [Related]
12. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
Kanthou C; Tozer GM
Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
[TBL] [Abstract][Full Text] [Related]
13. New oxazole-bridged combretastatin A-4 analogues as potential vascular-disrupting agents.
Mahal K; Biersack B; Schobert R
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):41-3. PubMed ID: 23259996
[No Abstract] [Full Text] [Related]
14. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
Rice L; Pampo C; Lepler S; Rojiani AM; Siemann DW
Microvasc Res; 2011 Jan; 81(1):44-51. PubMed ID: 20974154
[TBL] [Abstract][Full Text] [Related]
15. Combretastatins: more than just vascular targeting agents?
Greene LM; Meegan MJ; Zisterer DM
J Pharmacol Exp Ther; 2015 Nov; 355(2):212-27. PubMed ID: 26354991
[TBL] [Abstract][Full Text] [Related]
16. An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510.
van Wijngaarden J; Snoeks TJ; van Beek E; Bloys H; Kaijzel EL; van Hinsbergh VW; Löwik CW
Biochem Biophys Res Commun; 2010 Jan; 391(2):1161-5. PubMed ID: 20004648
[TBL] [Abstract][Full Text] [Related]
17. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
[TBL] [Abstract][Full Text] [Related]
18. In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents.
Cui MT; Jiang L; Goto M; Hsu PL; Li L; Zhang Q; Wei L; Yuan SJ; Hamel E; Morris-Natschke SL; Lee KH; Xie L
J Med Chem; 2017 Jul; 60(13):5586-5598. PubMed ID: 28653846
[TBL] [Abstract][Full Text] [Related]
19. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
20. Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.
Gevertz JL
Adv Exp Med Biol; 2016; 936():191-208. PubMed ID: 27739049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
